文献速递特殊人群用药药物不良反应与药物警戒

曲氟尿苷/替匹嘧啶在晚期实体瘤伴肝功能不全患者中的安全性、耐受性和药代动力学研究

Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
PubMed 文献 · Br J Clin Pharmacol · 2019-03-28

这项I期开放标签非随机研究评估了FTD/TPI在晚期实体瘤(除乳腺癌)伴不同程度肝功能不全患者中的安全性、耐受性和药代动力学,以提供剂量建议。结果显示,FTD/TPI可在肝功能正常和轻度不全患者中安全给药,无需初始剂量调整;但因中度不全患者出现3/4级血胆红素升高,不推荐用于中度或重度肝功能不全患者。

要点

  • FTD/TPI在肝功能正常和轻度不全患者中可安全使用,无需初始剂量调整。
  • 中度肝功能不全患者中5/6出现≥3级胆红素升高,不推荐使用FTD/TPI。
  • 未纳入重度肝功能不全患者,但结论不推荐用于中度或重度肝功能不全。

核心结论

  • FTD/TPI可在肝功能正常和轻度肝功能不全的晚期实体瘤患者中安全给药,无需初始剂量调整。
  • 因中度肝功能不全患者出现3级或4级血胆红素升高,FTD/TPI不推荐用于中度或重度肝功能不全患者。

研究设计与样本

  • I期、开放标签、非随机研究,计划纳入年龄≥18岁、晚期实体瘤(除乳腺癌)且肝功能正常或按美国国家癌症研究所标准判定为轻度、中度或重度肝功能不全的患者。
  • 给药方案为FTD/TPI 35 mg/m2口服,每日两次,每28天周期的第1-5天和第8-12天给药。

主要发现

  • 总体有12例患者(50.0%)发生至少1起导致研究终止的不良事件。
  • 中度肝功能不全队列中,6例患者中有5例出现≥3级胆红素升高。
  • 轻度队列和中度队列的FTD稳态AUC分别降低18%和22%,但TPI的AUC未见明显变化。

关键数值与推荐

  • 肝功能正常和轻度肝功能不全患者:FTD/TPI无需初始剂量调整即可安全给药。
  • 中度肝功能不全患者:因出现3级或4级血胆红素升高,不推荐使用FTD/TPI。
  • 重度肝功能不全患者:不推荐使用FTD/TPI。

临床怎么用

  • 对于晚期实体瘤伴肝功能正常或轻度肝功能不全的患者,可按标准剂量使用FTD/TPI,无需初始减量。
  • 对于中度或重度肝功能不全的患者,应避免使用FTD/TPI。
  • 使用FTD/TPI期间应监测胆红素等肝功能指标,尤其对肝功能不全患者。

局限性

  • 研究为开放标签、非随机设计。
  • 中度肝功能不全队列样本量仅6例,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Trifluridine/tipiracil (FTD/TPI) prolongs survival in refractory metastatic colorectal cancer, but limited data exist on its use in patients with hepatic impairment. This Phase I, open-label, nonrandomized study investigated the safety, tolerability and pharmacokinetics of FTD/TPI in patients with advanced solid tumours (except breast cancer) and varying degrees of hepatic impairment, to provide dosing recommendations. METHODS: Patients aged ≥18 years with advanced solid tumours and normal hepatic function, or mild, moderate or severe hepatic impairment according to National Cancer Institute criteria, were planned to be enrolled. Patients received FTD/TPI 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle. RESULTS: Twenty-four patients were enrolled to the normal hepatic function (n = 8) and mild (n = 10) and moderate (n = 6) hepatic impairment cohorts. Overall, 12 patients (50.0%) had at least 1 adverse event leading to study discontinuation. In the moderate hepatic impairment cohort, 5 of 6 patients experienced grade ≥ 3 elevation in bilirubin. No patients with severe hepatic impairment were enrolled. FTD area under the curve at steady state decreased by 18% and 22% in the mild and moderate cohorts, respectively; however, no clear change was observed in TPI area under the curve. CONCLUSIONS: FTD/TPI can be safely administered in patients with normal hepatic function and mild hepatic impairment, with no initial dose adjustment. FTD/TPI is not recommended for use in patients with moderate hepatic impairment because of findings of grade 3 or 4 increased blood bilirubin. Therefore, FTD/TPI is not recommended for patients with moderate or severe hepatic impairment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Saif MW, Rosen L, Rudek MA, et al. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol. 2019. PMID: 30628113. doi:10.1111/bcp.13856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。